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ABSTRACT
Paediatric brain tumours have a high mortality rate and are the most common 
solid tumour of childhood. Identification of high risk patients may allow for better 
treatment stratification. Magnetic Resonance Spectroscopy (MRS) provides a non-
invasive measure of brain tumour metabolism and quantifies metabolite survival 
markers to aid in the clinical management of patients. Glycine can be identified using 
MRS and has been recently found to be important for cancer cell proliferation in 
tumours making it a valuable prognostic marker. The aims of this study were to 
investigate glycine and its added value to MRS as a prognostic marker for paediatric 
brain tumours in a clinical setting.
116 children with newly diagnosed brain tumours were examined with short 
echo-time MRS at the Birmingham Children’s Hospital and followed up for five years. 
Survival analysis was performed using Cox regression on the entire metabolite basis 
set with focus on glycine and three other established survival markers for comparison: 
n-acetylaspartate, scyllo-inositol and lipids at 1.3 ppm. Multivariate Cox regression 
was used in conjunction with risk values to establish if glycine added prognostic 
power when combined to the established survival markers. 
Glycine was found to be a marker of poor prognosis in the cohort (p < 0.05) 
and correlated with tumour grade (p < 0.01). The addition of glycine improved the 
prognostic power of MRS compared to using the combination of established survival 
markers alone. 
Tumour glycine was found to improve the MRS prediction of reduced survival in 
paediatric brain tumours aiding the non-invasive assessment of these children. 
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INTRODUCTION
Paediatric brain tumours are the most common solid 
tumour of childhood and the largest cause of cancer death 
in that patient group. Identification of high risk patients 
may allow for better treatment stratification and more 
effective disease management. Treatment may include 
surgical resection, radiation therapy and chemotherapy, 
with specific protocols based on tumour diagnosis 
and clinical risk factors including age at diagnosis, 
histopathological and molecular features and radiological 
imaging features [1]. Despite known risk factors, it can be 
difficult to identify patients in a timely manner who may 
respond poorly to treatment. Establishing non-invasive 
biomarkers of prognosis in paediatric brain tumours prior 
to surgery would enhance clinical management, improve 
disease monitoring and help to reduce treatment-related 
damage. 
                                               Research Paper
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Magnetic Resonance Spectroscopy (MRS) provides 
a non-invasive measure of brain tumour metabolism, 
which can identify and quantify metabolite survival 
markers to aid in the clinical management of patients [2]. 
MRS has been previously used to identify both diagnostic 
and prognostic metabolite markers in adult and paediatric 
brain tumours [3]. Particular metabolites such as high 
lipids at 1.3 ppm (TLM 1.3 ppm) and scyllo-inositol 
(S-Ins) and glutamate (Glu) have been shown to reflect 
poor survival, whilst high n-acetylaspartate (NAA) and 
glutamine (Gln) has been shown to be a marker of good 
outcome in paediatric brain tumours [4, 5]. Glycine (Gly) 
is an additional metabolite that can be identified and 
quantified using MRS, and recent evidence suggests that 
it may be a valuable prognostic marker [5–7]. 
Gly is a conditionally essential amino acid, 
which has several physiological roles including as an 
inhibitory neurotransmitter in the central nervous system, 
cytoprotection, protein synthesis, extracellular structural 
support and an important role in the one-carbon metabolic 
cycle [8]. Notably raised in brain tumours relative to 
normal brain [9], elevated Gly has also been shown to 
distinguish high grade tumours, and has been proposed as 
a marker of increased malignancy in both paediatric and 
adult brain tumours [6, 10, 11]. Recent work also shows 
that an association between Gly concentration and/or 
related enzymes and prognosis is evident in many other 
tumours including breast, thyroid and colorectal cancer 
[12–15]. Furthermore, rapidly proliferating cells have 
recently been found to display an increased reliance on 
Gly consumption and synthesis, suggesting an important 
role for Gly in cancer metabolism [7]. It is therefore 
increasingly relevant to investigate Gly as a potential 
biomarker of prognosis in brain tumours and to firmly 
establish non-invasive ways of measuring Gly in patients. 
Although histology remains the gold standard for 
diagnosis, not all brain tumours are surgically resected 
or biopsied and non-invasive MRS has proven valuable 
in the clinical management of these patients [16]. 
Metabolites measured by MRS have also been shown 
to provide additional information, complimentary to 
histology [3, 4, 17, 18]. Although prior work has shown 
that Gly is a potential marker of tumour grade in the brain, 
Gly concentration at diagnosis has not been previously 
associated with patient survival. Therefore, the aims 
of this study were to investigate Gly concentration as a 
prognostic marker across a cohort of paediatric brain 
tumours and to assess the added value it provides to the 
prognosis prediction potential of MRS in a clinical setting. 
RESULTS
Patients
The brain tumour cohort consisted of 98 patients 
after quality control criteria were applied, with 18 removed 
during the quality control process. The patient cohort 
consisted of 81 biopsied tumours and 17 unbiopsied 
tumours. There were 59 survivors (60%) and 39 non-
survivors by the end of the 5 year follow up period. All 
patient deaths were as a result of their disease. The mean 
age (±SD) of the patient cohort at diagnosis was 7.51 (±5.4) 
years, and 71% of patients were male. Age and gender 
were not found to be predictive of survival in this cohort 
with log-rank values of 1.2 and 0, respectively. The patient 
tumour type distribution with associated frequency and 
deaths within the 5 years is shown in Table 1. The tumour 
type survival rates in the cohort were consistent with 
prognosis expectations for the more common tumour types. 
Glycine is a marker of poor prognosis
Gly was found to be a predictor of poor prognosis 
(p < 0.03) in the patient cohort based on a univariate Cox 
regression analysis and a concentration cutoff of 0.55 mM 
(Figure 1, Table 2). Gly concentrations were found to be 
significantly higher the high grade tumour group (2.00 
± 2.52 mM) compared with the low grade tumour group 
(0.53 ± 0.97 mM; p < 0.01) (Table 1) and concentrations 
correlated with WHO grade of the tumours, (r = 0.44; p 
< 0.01). Example spectra from a medulloblastoma patient 
case highlight high Gly levels with the associated poor 
prognosis of the patient (Figure 2). Additional spectra 
of an ependymoma and pilocytic astrocytoma patient 
(Supplementary Figures 1 and 2) highlight that low Gly 
concentration also predicted the survival of the patient 
correctly in those cases. Gly was also found to be a 
significant survival marker after the medulloblastoma 
group was removed from the analysis (p < 0.05). 
To validate the Gly concentrations a comparison 
between matched short and long echo-time MRS was 
conducted and a strong correlation was found (r = 0.91; 
p < 0.001). An example long echo spectrum and a graph 
of the Gly concentration correlation between echo times is 
shown in Supplementary Figures 3 and 4. 
Established survival marker comparisons
Established survival metabolite markers TLM 1.3 
ppm and S-Ins were also found to be predictors of poor 
prognosis and NAA was found to be a predictor of good 
prognosis (Figure 1, Table 2). Hazard ratios and log-rank 
tests showed that the prognosis prediction potential of Gly 
was similar to other individual metabolite markers (Table 2). 
The addition of glycine improves the MRS 
prediction of prognosis
A multivariate Cox regression was used to combine 
metabolite markers in the analysis. The log-rank test 
results of 14.4 and 7.7 for the analysis with and without 
Gly, respectively, show the survival prediction was 
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significantly higher with Gly in the analysis (p < 0.05). 
This result was also seen in the Kaplan Meier curves based 
on risk values, where larger separation of the high risk and 
low risk groups was seen in the analysis with Gly included 
(Figure 3). 
MRS prediction of survival in individual tumour 
types
Mean MRS relative risk for tumour types with 
n > 2 were reported in Table 1. The MRS relative risk 
value predicted tumour types of good prognosis in this 
cohort, pilocytic astrocytoma, unbiopsied optic pathway 
glioma and tectal plate glioma all had mean values of 
less than 1. Poor prognosis tumour types in this cohort, 
medulloblastoma, atypical teratoid rhabdoid tumour, 
glioblastoma and ependymoma, were also identified 
well through MRS relative risk with mean values greater 
than 1. However, prognosis for Diffuse Intrinsic Pontine 
Glioma (DIPG), diffuse astrocytoma and germinoma 
tumour types was not well predicted through relative risk 
alone. Observing individual results, MRS relative risk in 
these tumour types only predicted the correct prognosis in 
2 out of 9 DIPG patients, 2 out of 4 diffuse astrocytoma 
and 1 out of 3 germinoma patients. The high grade tumour 
group had a high MRS relative risk and low grade tumour 
group had a low MRS relative risk
DISCUSSION
This study has established that tumour Gly 
concentration, measured non-invasively by MRS, is a 
prognostic marker in a cohort of paediatric brain tumour 
patients. A higher concentration of Gly was significantly 
associated with reduced survival, indicating that Gly is a 
marker of poor prognosis across a wide range of paediatric 
brain tumours. Furthermore, the addition of Gly to the 
existing set of metabolites previously associated with 
Table 1: A summary of patient tumour type diagnoses in the cohort, based on clinical information, imaging and 
histopathology where available, patient deaths, mean metabolite (Gly, NAA, TLM 1.3 ppm and S-Ins ) concentrations 
and mean relative risk for the groups (where n > 2)
Tumour Type Patients (n) 
Deaths 
(n)
Gly
 (SD), mM
NAA
(SD), mM
TLM 1.3 ppm 
(SD), mM
S-Ins 
(SD), mM
MRS 
Relative 
Risk
Pilocytic 
Astrocytoma 23 1 0.58 (1.13) 0.74 (0.78) 8.35 (6.47) 0.01 (0.06) 0.74
Unbiopsied Optic 
Pathway Glioma 6 0 0 (0) 1.34 (1.01) 2.24 (2.77) 0.10 (0.23) 0.50
Ependymoma 5 3 3.49 (5.98) 0.25 (0.18) 14.21 (9.66) 0.29 (0.32) 1.29
Diffuse 
Astrocytoma 4 2 0.34 (0.56) 0.69 (0.72) 9.55 (10.45) 0.10 (0.18) 0.82
Diffuse Intrinsic 
Pontine Glioma 9 7 0.56 (0.84) 1.59 (1.63) 5.08 (6.58) 0.31 (0.27) 0.92
Atypical Teratoid 
Rhabdoid Tumour 3 3 0.94 (0.91) 0.14 (0.12) 33.73 (22.14) 0.11 (0.18) 2.16
Medulloblastoma 21 13 3.57 (2.78) 0.23 (0.25) 21.05 (17.34) 0.37 (0.37) 1.96
Tectal Plate Glioma 4 0 0.02 (0.05) 1.26 (1.06) 1.83 (1.66) 0.06 (0.08) 0.64
Glioblastoma 5 5 0.66 (0.81) 0.42 (0.19) 16.93 (8.99) 0.18 (0.13) 1.43
Germinoma 3 0 0.62 (0.52) 0.48 (0.64) 11.28 (7.76) 0.14 (0.18) 1.47
High Grade 
(III & IV) 38 23 2.00 (2.52) 0.46 (0.61) 18.29 (17.30) 0.24 (0.31) 1.74
Low Grade 
(I & II) 49 15 0.53 (0.97) 0.92 (1.01) 7.06 (6.79) 0.11 (0.21) 0.65
Ungraded 11 1 0.56 (0.90) 0.57 (0.60) 15.95 (11.80) 0.19 (0.34) 1.15
The cohort was also split into ungraded (n = 11), High and low WHO grade groups (n = 87) for metabolite concentration 
and relative risk comparison. Rarer tumour types, where n < 2, were included in the high grade, low grade and ungraded 
groups and also included in the survival analysis.
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survival in brain tumours improved the overall prognosis 
prediction potential of MRS. We also detected a significant 
correlation between tumour grade and Gly concentration 
in the smaller cohort of cases where the tumour was 
biopsied. Although these results agree with prior work of 
Gly concentration as a marker of malignancy [6, 10, 11, 
19–23], this is the first study to formally show that Gly is 
a predictor of survival and not just grade in brain tumours. 
Recent evidence suggests that Gly has a particularly 
important role in cancer metabolism perhaps explaining 
why Gly concentration is higher in more aggressive 
tumours. Gly is particularly linked to the one-carbon 
metabolic cycle whereby non-essential amino acids donate 
carbon units to produce complex metabolic reactions 
within folate, methionine and transsulfuration pathways 
including regulation of cell biosynthesis, redox status 
and epigenetic status [8, 24, 25]. Gly metabolism and 
the one-carbon metabolic cycle has been directly linked 
to increased cellular proliferation via the Gly cleavage 
system in several cancers including non-small cell lung 
cancer, breast and thyroid cancer [14, 15, 26]. This is 
evidenced by the upregulated activity of Gly metabolic 
enzyme Gly decarboxylase (GLDc) and an association 
between poor prognosis subgroups and increased GLDc 
staining using immunohistochemistry in these tumours 
[14, 15, 27]. Indeed the gene that underlies GLDc is 
now being proposed as a metabolic oncogene, and novel 
therapies specifically targeting Gly metabolism via the 
one-carbon cycle are being proposed to disrupt cellular 
proliferation and prevent tumourigenesis [26]. Although 
there is no evidence to date of increased GLDc activity 
in brain tumours, it seems likely that Gly metabolic 
activity may be upregulated, particularly in high grade 
brain tumours. An association between increased tissue 
Gly concentration and progression free survival in ex vivo 
colorectal cancer tissue has been the only study to date to 
link Gly concentration measured by MRS with adverse 
prognostic outcome [13]. 
The detection of Gly by MRS is potentially hindered 
owing to the spectral overlap with Myo-Insositol ( M-Ins). 
However, literature reports provide evidence that Gly 
in tumours can be reliably detected using the methods 
applied in this study. [6, 28]. M-Ins levels are known to 
decrease more rapidly than Gly levels with echo-time, 
Figure 1: Kaplan Meier 5-year survival curves for the patient cohort. Gly (A), NAA (B), TLM 1.3ppm (C) and S-Ins (D) are 
presented. High & low concentration groups are based on optimised cut-off values.
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hence the Gly peak fit in long echo-time MRS is more 
robust. The strong correlation between the matching 
short and long echo-time Gly concentration found in this 
study (Supplementary Figure 4) provides confidence that 
Gly in the short echo-time MRS has been fitted well. 
Additionally, M-Ins has a peak at 4.06 ppm, which can 
be used to aid distinction between Gly and M-Ins if a 
large contribution of M-Ins is present in the 3.56 ppm 
peak. This peak is modelled and fitted by TARQUIN as 
part of the quantitative analysis and may contribute to the 
Table 2: A summary of univariate Cox regression survival hazard ratios, log-rank test and significance values results 
for the individual metabolite survival markers Gly, NAA, TLM 1.3 ppm and S-Ins 
Gly TLM 1.3 ppm S-Ins NAA
Hazard ratio 2.29 2.30 2.14 0.49
Range:
low-upper 1.17–4.45 1.14–4.32 1.13–4.05 0.25-0.94
Log-rank 6.30 4.70 6.50 5.80
Likelihood p-value 0.008 0.01 0.02 0.03
Figure 2: An example medulloblastoma patient MRS spectrum with TARQUIN peak fits of Gly, M-Ins and fit residuals 
shown. The medulloblastoma spectrum shows high Gly, low M-Ins and this patient died within the 5 year follow-up period. Examples of 
an ependymoma and pilocytic astrocytoma spectrum are additionally shown in Supplementary Materials. 
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ability of the method to distinguish Gly and M-Ins in this 
study. Other groups have reported that Gly concentrations 
measured in brain tumours by in vivo short echo-time 
MRS at 1.5T correlate with Gly levels determined from 
ex vivo tissue samples and other in vivo methods [6, 28]. 
The concentrations of Gly reported in this study (Table 1) 
are comparable to the reported literature values for low 
grade and medulloblastoma tumours [6]. Medulloblastoma 
tumours have higher Gly levels compared with other 
tumours and relatively poor prognosis. However, removing 
these tumours from the analysis we still found Gly to be 
a marker of overall survival, showing that Gly was not 
purely a marker of this tumour type. Gly concentrations 
correlated with grade in this study, which is in agreement 
with reported literature studies and supports the measure 
as a survival marker for brain tumours [6, 7, 11, 28]. 
It was also important to establish the added value 
of Gly to the overall survival prediction of metabolite 
markers measured by MRS. We found that NAA, S-Ins 
and TLM 1.3 ppm were individual markers of prognosis 
in this cohort, which is consistent with prior results 
reported in paediatric brain tumours [4, 29]. Glutamine has 
previously been reported as a marker of good prognosis 
but was not found to be so in this study [4]. Glutamine 
is poorly determined by MRS at 1.5T and further study 
of this metabolite at higher field strength are warranted. 
NAA is regarded as a marker of neuronal activity, and 
while its role in tumours is not well understood, higher 
concentrations of NAA detected in brain tumours is 
associated with better outcome [29]. Using the current 
methodology, the peak around 2 ppm is largely fitted to 
the NAA spectrum consistent with many previous studies. 
However, important contributions to this peak may arise 
from other molecules and the biological interpretation of 
the prognostic significance of NAA should be undertaken 
with caution [30]. Additionally, contributions to the NAA 
peak can occur from non-tumour tissue if the voxel is close 
to the tumour edge. However, review of the cases with 
Figure 3: Kaplan–Meier survival curves for the patient cohort based on a risk analysis and multivariate Cox regression 
of the four metabolite survival markers, Gly, NAA, S-Ins, TLM 1.3 ppm. The two Kaplan–Meier curves show the analysis 
without Gly (A) and with Gly included (B) in the analysis. Median cutoffs were used to define the low and high-risk groups.    
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high NAA values showed that the majority of cases with 
high NAA were diffuse tumours with voxels generally 
well within the radiological abnormality.
S-Ins has been previously associated with poor 
prognosis in paediatric brain tumours, however, its role in 
tumour metabolism is not well known, warranting further 
investigation [4, 31]. Lipids are well documented as being 
associated with poor prognosis in both paediatric and adult 
brain tumour patients being associated with apoptosis, 
necrosis and cytoplasmic lipid droplets [32–35]. The 
results showed Gly complimented the established survival 
markers and increased prognostic value. Therefore, the 
addition of the Gly measure in MRS provides increased 
power of the technique as a prognostic tool [4]. 
There is clinical interest in establishing non-invasive 
markers of prognosis in individual tumour types and the 
prediction of individual outcome. In this study this was 
preliminarily investigated through the MRS derived 
relative risk value. The high grade grouping of tumours 
had a significantly greater relative risk value than the low 
grade tumour group. Looking at more specific tumour 
types, the relative risk value was good at predicting 
prognosis for most tumour types, but performed the best 
for groups that consisted of high numbers of patients with 
either good or poor survival, e.g. pilocytic astrocytoma 
and atypical teratoid rhabdoid tumours. The exceptions 
to this provide an interesting insight into the information 
provided by MRS. Diffuse astrocytoma and DIPG tumour 
groups progress to a higher grade prior to death and may 
evolve to a more aggressive MRS profile during tumour 
progression [36]. Germinomas are very rapidly growing 
tumours which metastasise readily, consistent with their 
MRS profile, but are extremely sensitive to treatment. 
MRS profiles therefore appear to provide information 
on inherent tumour properties of growth and malignant 
potential rather than response to treatment. In future 
work, larger cohorts should investigate specific markers 
of survival for individual tumour types and the ability of 
MRS to predict response to specific treatments. 
Non-invasive measures of diagnosis and prognosis 
in brain tumours are becoming increasingly important. 
This is particularly evident given that approximately a 
quarter of paediatric brain tumours are not biopsied and 
therefore receive no histological diagnosis. In this instance, 
metabolites can provide additional clinical information 
non-invasively. It is important to note that MRS has been 
successfully used to discriminate relapse from treatment 
related effects, to non-invasively identify tumour type 
and to provide additional molecular genetic information 
to aid in clinical management [4, 17, 18, 37, 38]. 
However, it can remain difficult to identify patients at 
diagnosis who respond poorly to treatment, despite known 
molecular and histopathological risk factors. Metabolite 
prognostic markers show potential for providing 
additional information to aid in clinical decision making 
prior to surgery. Hence the current work showing Gly, in 
combination with established MRS survival markers, as a 
prognostic marker across a range of brain tumours shows 
promise for implementation into clinical practice, and may 
prove useful for risk stratification and enhanced disease 
management.
In conclusion, Gly was found to be a marker of poor 
overall survival using non-invasive MRS in paediatric 
brain tumours. This is an important finding as Gly has been 
recently found to be vital for cancer cell proliferation in 
tumours. The addition of Gly to other reported metabolite 
survival markers improved the prognosis prediction 
potential of MRS, thus, improving MRS as a tool for 
aiding in the clinical management of brain tumour patients. 
MATERIALS AND METHODS
Patients
116 children with newly diagnosed brain tumours 
were examined with MRS prior to treatment as part of 
their clinical investigations at the Birmingham Children’s 
Hospital. The accrual period was between September 
2003 and July 2009, with all patients followed up for five 
years. The cohort overlaps with that from a previously 
reported study and so should not be considered a an 
independent validation of the biomarkers reported in that 
study [4]. Rather it is an investigation of the value of 
glycine as a biomarker and its added value compared with 
other metabolite biomarkers. Clinical data was obtained 
through the West Midlands Tumour Registry and clinical 
records, which included gender, patient age at diagnosis 
and dates of death. Tumour diagnosis was confirmed 
by a multidisciplinary team using histopathology, along 
with clinical and radiological information. All graded 
tumours were biopsy proven. Ungraded tumours were 
either unbiopsied or biopsied and found to have a WHO 
diagnosis with no associated grade. Patients were given 
standard treatment based on their diagnosis, tumour stage, 
age and extent of resection. Treatment included a variety 
of methods including surgical resection, radiotherapy and 
chemotherapy according to their clinical need and not 
based on Gly levels. Study approval was gained through 
research ethics committee and signed consent given by 
parents or guardians. The study was designed following 
the REMARK criteria [39].
MRI – protocols and analysis
MRI and MRS were acquired pre-treatment on a 
1.5T Siemens Symphony Magnetom with a single-channel 
head coil and 1.5T GE Signa Excite scanner with an 
8-channel head coil. MRI included standard T1- and T2-
weighted images of the brain, diffusion-weighted imaging 
followed by gadolinium contrast administration and then 
further T1-weighted imaging. MRI was utilised to provide 
anatomical reference to the primary tumour and measure 
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contrast enhancement within the tumour. The MRS voxel 
was placed within the solid component of the primary 
tumour measuring 1.5 or 2 cm sided cube depending on the 
size of the tumour. PRESS (Point Resolved Single Voxel 
Spectroscopy) localisation was used with a repetition time 
of 1500 ms and an echo-time of 30 ms. Fifteen patients 
had matching long echo-time (135 ms) MRS data, which 
was analysed as a validation method for the Gly fit. Water 
suppressed data were acquired with 256 or 126 repetitions, 
depending on voxel size for signal averaging. Water 
unsuppressed data were additionally taken as a metabolite 
concentration reference. MRS data were transferred from 
the scanner to a PUKKAJ PACs system (version 6.6.1) 
used for storage of research and advanced MRI data. 
Unprocessed MRS signals were analysed using the 
TARQUIN [40] software package (version 4.3.6). Each 
spectrum was fitted with the following metabolites in the 
basis set; Alanine (Ala), Aspartate (Asp), Citrate (Cit), 
Creatine (Cr), γ-aminobutyric acid (GABA), Glycero-
PhosphoCholine (GPC), Glucose (Glc), Glutamine (Gln), 
Glutathione (Glth), Glutamate (Glu), Glycine (Gly), 
Myo-Inositol (M-Ins), Lactate (Lac), Lipids (0.9 ppm, 
1.3 ppm, 2.0 ppm), Macromolecules (0.9 ppm, 1.2 ppm, 
1.4 ppm, 1.7 ppm, 2.0 ppm), N-AcetylAspartate (NAA), 
N-AcetylaspartylGlutamate (NAAG), PhosphoCholine 
(PCh), PhosphoCreatine (PCr), Scyllo-Inositol (S-Ins) 
and Taurine (Tau). No restrictions were placed on 
relative intensities of the lipid and macromolecule peaks 
fitted. For statistical tests the following metabolite pairs 
were combined as they are known to be difficult to 
resolve reliably: NAA and NAAG (TNAA), PCh and 
GPC (TCho), PCr and Cr (TCr) and finally lipids and 
macromolecules to TLM 0.9 ppm, TLM 1.3 ppm, TLM 
2.0 ppm. Metabolite concentrations were scaled relative 
to the water signal with a water molarity assumed to be 
35880 mM [40].
Individual spectra were inspected by two expert 
spectroscopists blinded to the survival data and excluded 
if they did not meet one or more of the quality control 
criteria. These were displaced voxel location (too close 
to lipid containing structures), unstable spectral baseline, 
presence of spectral artifacts, signal-to-noise ratio (SNR) 
<5, overall metabolite linewidths >0.15 ppm and water 
linewidth >10 Hz. Voxels containing more than 10% of 
uninvolved brain as assessed by the conventional MRI 
were excluded from the analysis.
Statistical analysis
All metabolites in the basis set were utilised to 
test whether they were markers of prognosis through a 
univariate Cox regression, log-rank test and Kaplan–
Meier analysis using a median metabolite concentration 
cutoff. Metabolites that were found to be significant 
(p < 0.05) had their metabolite concentration cutoff 
optimised iteratively based on the lowest p-value. Gly and 
established metabolite survival markers, TLM 1.3 ppm, 
NAA and S-Ins were additionally optimised in the same 
manner. Metabolite concentrations for all tumours were 
calculated, and mean values for each tumour diagnostic 
group where n > 2 are shown in Table 1. Metabolite 
concentrations of rare tumour types, where n < 2, were 
not shown in Table 1 but were included in the survival 
analysis. These included 1 anaplastic ependymoma, 2 
astrocytomas, 1 ganglioglioma, 1 mixed cell germ tumour, 
2 choroid plexus papilloma, 1 pineoblastoma, 1 secreting 
germ cell tumour and 1 biopsied metastatic tumour. The 
Gly concentration is known to be high in medulloblastoma 
tumour therefore a univariate Cox regression analysis of 
Gly concentration was performed with these tumours 
removed to assess any potential bias in survival from 
this group. All tumours with associated WHO grades 
were split into low grade (grade I and II) and high grade 
(grade III and IV) groups with the remainder placed into 
the ungraded group to compare mean Gly concentration 
values (Table 1). A Spearman’s correlation test was also 
performed establish if WHO grade correlated with Gly 
concentration. Additionally, Gly concentrations from the 
long and short echo-time MRS in the same scan session 
in patients where available were tested for correlation to 
validate the short echo-time Gly fits. 
MRS provides multiple markers of tumour 
prognosis, hence while establishing new individual 
markers is of clinical interest the combination of markers 
may provide more predicting power. Therefore, the 
added value of Gly to the survival prediction of MRS 
was assessed by combining established survival markers 
with Gly included or excluded from a multivariate Cox 
regression analysis. Risk prediction analysis, using the 
multivariate Cox regression model, was performed to 
assess the MRS prognosis prediction, with and without 
Gly included. This was visualised through Kaplan–Meier 
survival curves using median risk score cutoffs. 
Risk analysis, was also performed to assess the 
ability of MRS as a whole to predict individual tumour 
type prognosis (Table 1). Survival analyses were 
performed in R statistical software using the survival 
library. A p-value of < 0.05 was deemed significant in all 
tests.
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